Alnylam Pharmace. buy Royal Bank of Canada
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 04.09.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time.Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w |
---|---|
Alnylam Pharmace. | - |
iShares Core DAX® | -0.372% |
iShares Nasdaq 100 | -1.950% |
iShares Nikkei 225® | -1.690% |
iShares S&P 500 | -0.399% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Royal_Bank_of_Canada for Alnylam Pharmace.
Alnylam Pharmace.
28.08.23
28.08.24
29.08.24
Alnylam Pharmace.
18.08.23
18.08.24
19.08.24
Alnylam Pharmace.
04.08.23
04.08.24
05.08.24
Alnylam Pharmace.
25.07.23
25.07.24
26.07.24